7-octylindolactam V: only (-)-isomer has carcinogenic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 159320 |
CHEMBL ID | 285801 |
SCHEMBL ID | 10032033 |
MeSH ID | M0228069 |
Synonym |
---|
PDSP2_001363 |
PDSP1_001379 |
7-octylindolactam v |
CHEMBL285801 , |
109346-66-9 |
bdbm50057514 |
13-hydroxymethyl-10-isopropyl-9-methyl-5-octyl-3,9,12-triaza-tricyclo[6.6.1.0*4,15*]pentadeca-1,4,6,8(15)-tetraen-11-one (n-octyl-ilv) |
(10s,13s)-13-hydroxymethyl-10-isopropyl-9-methyl-5-octyl-3,9,12-triaza-tricyclo[6.6.1.0*4,15*]pentadeca-1,4,6,8(15)-tetraen-11-one |
3h-pyrrolo(4,3,2-gh)-1,4-benzodiazonin-3-one, 1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-9-octyl-, (2s-(2r*,5r*))- |
3h-pyrrolo[4,3,2-gh]-1,4-benzodiazonin-3-one,1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-9-octyl-,(2s,5s)- |
SCHEMBL10032033 |
5-(hydroxymethyl)-1-methyl-9-octyl-2-(propan-2-yl)-2,5,6,8-tetrahydro-1h-[1,4]diazonino[7,6,5-cd]indol-3-ol |
DTXSID60911123 |
(10s,13s)-13-(hydroxymethyl)-9-methyl-5-octyl-10-propan-2-yl-3,9,12-triazatricyclo[6.6.1.04,15]pentadeca-1,4,6,8(15)-tetraen-11-one |
PD119412 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Protein kinase C gamma type | Homo sapiens (human) | Ki | 0.0012 | 0.0012 | 0.4253 | 6.0000 | AID164025 |
Protein kinase C beta type | Homo sapiens (human) | Ki | 0.0004 | 0.0004 | 0.6924 | 6.0000 | AID163193 |
Protein kinase C alpha type | Homo sapiens (human) | Ki | 0.0005 | 0.0002 | 1.0945 | 6.9600 | AID163026 |
Protein kinase C delta type | Mus musculus (house mouse) | Ki | 0.0001 | 0.0001 | 0.5276 | 7.0800 | AID164207 |
Protein kinase C epsilon type | Homo sapiens (human) | Ki | 0.0010 | 0.0004 | 0.9797 | 6.0000 | AID163837 |
Protein kinase C delta type | Homo sapiens (human) | Ki | 0.0008 | 0.0003 | 0.9489 | 6.9600 | AID163526 |
RAS guanyl-releasing protein 1 | Rattus norvegicus (Norway rat) | Ki | 0.0009 | 0.0009 | 0.0017 | 0.0025 | AID166231 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (87.50) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.97) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |